TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11135795

Group type: EXPERIMENTAL
Intervention: Parent-child autotutorial (PCAT) programme, a 10-week home-based self-instruction nutrition education programme
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Nutrition counselling from a registered dietitian
Number of subjects: 227

Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Nutrition education (PCAT or counselling)
Number of subjects: 227
Study: 9100622

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg three times daily
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1906
Study: 7505523

Group type: EXPERIMENTAL
Intervention: Continuous diluted intravesical instillation of bleomycin (120 mg/2,000 ml saline solution/day for 3 days), instillation BCG (40 mg/40 ml saline solution/weekly 6 times), and UFT (400 mg orally/day for 2 years maximum)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No BCG instillation (UFT and bleomycin only)
Number of subjects: 63
Study: 3569448

Group type: EXPERIMENTAL
Intervention: 120 mg ambroxol daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28937912

Group type: EXPERIMENTAL
Intervention: Postpartum contraceptive use
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rapid repeat pregnancy
Number of subjects: 161
Study: 27553626

Group type: EXPERIMENTAL
Intervention: Intensive quality improvement intervention for back pain including 6 one-hour training sessions for physicians, 5 days of training for physical therapists, individualized and group coaching of clinicians, and integration of the STarT Back tool into the electronic health record.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group receiving standard care without the intensive quality improvement intervention.
Number of subjects: 6
Study: 24929048

Group type: EXPERIMENTAL
Intervention: Neutral male faces as conditioned threat and safety cues
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neutral female faces as conditioned threat and safety cues
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fearful face paired with a shrieking scream as unconditioned stimulus
Number of subjects: 120
Study: 22147796

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 740

Group type: COMPARATOR
Intervention: Control (no male circumcision)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Male circumcision among female partners of HSV‐2-positive males
Number of subjects: 740

Group type: COMPARATOR
Intervention: Control (no male circumcision) among female partners of HSV‐2-positive males
Number of subjects: 740
Study: 20813866

Group type: EXPERIMENTAL
Intervention: Online predilution hemofiltration (HF)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Online predilution hemodiafiltration (HDF)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 146
Study: 18479381

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 45
Study: 20232195

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment (adequate analgesia, osteoporosis medication, individualized physiotherapy or braces)
Number of subjects: 0
Study: 15533635

Group type: EXPERIMENTAL
Intervention: Lipoprotein (a) concentrations during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoprotein (a) concentrations in severe pre-eclampsia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline lipoprotein (a) concentrations
Number of subjects: 0
Study: 12211220

Group type: EXPERIMENTAL
Intervention: Estrogen therapy in postmenopausal women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy to reduce cardiovascular risk
Number of subjects: 0
Study: 9756282

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: In vitro fertilization (IVF)
Number of subjects: 96
Study: 7871232

Group type: EXPERIMENTAL
Intervention: Paired presentation method
Number of subjects: 8

Group type: COMPARATOR
Intervention: Group presentation method
Number of subjects: 8

Group type: COMPARATOR
Intervention: Staff rankings
Number of subjects: 8
Study: 2947783

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 8
Study: 31314702

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 28927950

Group type: EXPERIMENTAL
Intervention: Kinect-based real-time audiovisual feedback (AVF) device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standing posture
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Kneeling posture
Number of subjects: 100
Study: 27289534

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation with dietary supplementation (WB-EMS & P)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 75
Study: 23878167

Group type: COMPARATOR
Intervention: IFX dose intensification (5 mg/kg every 4 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Interventions based on serum IFX and IFX antibody levels using the proposed algorithm
Number of subjects: 69
Study: 22076596

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (lifestyle modification)
Number of subjects: 12
Study: 20823380

Group type: EXPERIMENTAL
Intervention: Renal artery revascularization by stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with RAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-RAS patient controls and normal healthy individuals
Number of subjects: 0
Study: 18469151

Group type: EXPERIMENTAL
Intervention: Self-distanced analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immersed-analysis
Number of subjects: 0
Study: 15721999

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study: 16285179

Group type: EXPERIMENTAL
Intervention: Autologous tumour cell vaccine (n = 9)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Open vaccination (n = 12)
Number of subjects: 29
Study: 10099746

Group type: EXPERIMENTAL
Intervention: Early obstetrical discharge (24-48 hours)
Number of subjects: 2092

Group type: COMPARATOR
Intervention: Routine obstetrical discharge
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: Early obstetrical discharge
Number of subjects: 2092
Study: 9084515

Group type: EXPERIMENTAL
Intervention: 0.5% interpleural bupivacaine (10 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study: 1912105

Group type: EXPERIMENTAL
Intervention: m-CPP (up to 80 mg/day for 16 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7046482

Group type: EXPERIMENTAL
Intervention: Printed summary of the computerized medical record during T1 for internists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control visits for internists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study visits for surgeons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control visits for surgeons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study visits during T2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control visits during T2
Number of subjects: 0
Study: 30957646

Group type: EXPERIMENTAL
Intervention: Dementia care mapping for neurorehabilitation (DCM‐NR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 41
Study: 29432379

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.4 μg kg h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.6 μg kg h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg kg h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg kg h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 60
Study: 26766541

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg or 2.5 mg twice daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Warfarin (target international normalized ratio, 2‐3)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 200

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 200
Study: 25516016

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen three times a day for three days
Number of subjects: 500

Group type: COMPARATOR
Intervention: 200 mg mecillinam three times a day for three days
Number of subjects: 500
Study: 23649063

Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing 6% sodium fluoride and 6% calcium fluoride
Number of subjects: 21

Group type: COMPARATOR
Intervention: Gel containing 6% potassium nitrate and 0.11% fluoride ions
Number of subjects: 21
Study: 20970637

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (5% dextrose solution)
Number of subjects: 50
Study: 18489783

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily for 12 weeks (Group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily for 12 weeks (Group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Withdrawal of zafirlukast (both groups)
Number of subjects: 45
Study: 15634273

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 50 mg twice daily
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 300 mg once daily
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 225 mg twice daily
Number of subjects: 1973

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 1973
Study: 16036023

Group type: EXPERIMENTAL
Intervention: Ventricular assist devices as destination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smaller, more durable mechanical assist devices
Number of subjects: 0
Study: 10996579

Group type: EXPERIMENTAL
Intervention: Airway bacterial load
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bacterial load of 10(6) to 10(7) CFU/mL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bacterial load of 10(7) to 10(8) CFU/mL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bacterial load of 10(8) or greater CFU/mL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Colonization with Pseudomonas aeruginosa
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Colonization with nontypeable Hemophilus influenzae
Number of subjects: 160
Study: 9115022

Group type: EXPERIMENTAL
Intervention: Bronchodilator drugs
Number of subjects: 12301

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12301
Study: 8461646

Group type: EXPERIMENTAL
Intervention: Detailed information about potential complications
Number of subjects: 96

Group type: COMPARATOR
Intervention: Simple explanation of the facts
Number of subjects: 96
Study: 3546151

Group type: EXPERIMENTAL
Intervention: Ofloxacin (100 mg, b.i.d. for 7 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg, b.i.d. for 7 days)
Number of subjects: 35
Study: 30379815

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27368279

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study: 24880581

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing therapy (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual (n=10)
Number of subjects: 20
Study: 22520655

Group type: EXPERIMENTAL
Intervention: Healthier, alternative menu at a budget supermarket
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthier, alternative menu at a mid-range supermarket
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching from unhealthy mid-range supermarket menu to healthier, budget-outlet alternative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthier, alternative menu on the high street
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing diet at a budget supermarket
Number of subjects: 0
Study: 20424140

Group type: EXPERIMENTAL
Intervention: Lipid heparin infusion (LHI) inducing physiological elevations of FFAs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Discontinued insulin infusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous insulin supply
Number of subjects: 28
Study: 18793446

Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy (8 individual sessions over 12 weeks, home exercise program 4 times/week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physiotherapist-delivered OA education control treatment (8 individual sessions over 12 weeks)
Number of subjects: 90
Study: 16182685

Group type: EXPERIMENTAL
Intervention: Oral dietary supplements
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dietary counseling
Number of subjects: 13
Study: 12601099

Group type: EXPERIMENTAL
Intervention: (11)C-WAY 100635 PET in patients with PD
Number of subjects: 23
Study: 10855138

Group type: EXPERIMENTAL
Intervention: Taught session
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-study group
Number of subjects: 12
Study: 8580688

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 2232625

Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 159057

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (30 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29771596

Group type: EXPERIMENTAL
Intervention: ExPEC4V vaccine (4, 8, and 16 µg PS/serotype)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26659916

Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and dexamethasone
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Melphalan, prednisone, and thalidomide
Number of subjects: 1613
Study: 23109138

Group type: EXPERIMENTAL
Intervention: Group support (constructed support)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Family support (naturalistic support)
Number of subjects: 305
Study: 21998259

Group type: EXPERIMENTAL
Intervention: AHR strategy (titrating inhaled corticosteroid against mannitol PD(10))
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: AHR strategy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (reference strategy)
Number of subjects: 164
Study: 20480225

Group type: EXPERIMENTAL
Intervention: Celecoxib 800 mg/day during cycles 5-8
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg then 6 mg/kg IV every 3 weeks)
Number of subjects: 340

Group type: COMPARATOR
Intervention: No additional treatment (control for HER2-negative)
Number of subjects: 340

Group type: COMPARATOR
Intervention: No additional preoperative treatment (control for HER2-positive)
Number of subjects: 340
Study: 18705755

Group type: EXPERIMENTAL
Intervention: 100 mg Nigella sativa seed extract twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg Nigella sativa seed extract twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15744449

Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D levels below 20 ng/ml
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D levels below 30 ng/ml
Number of subjects: 986

Group type: COMPARATOR
Intervention: High mean 25OHD levels
Number of subjects: 986
Study: 14710908

Group type: EXPERIMENTAL
Intervention: 20 units of BTX‐A injected into each nasal cavity (total 40 units)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 units of BTX‐A injected into each nasal cavity (total 60 units)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 2 ml of isotonic saline (placebo)
Number of subjects: 34
Study: 10070048

Group type: EXPERIMENTAL
Intervention: Mild hyperglycemia (approximately 10 mmol/l)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Euglycemia (approximately 4 mmol/l)
Number of subjects: 9
Study: 7668024

Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin q.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin i.v. (single dose)
Number of subjects: 10
Study: 2107773

Group type: EXPERIMENTAL
Intervention: EMLA and glyceryl trinitrate ointment
Number of subjects: 100

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glyceryl trinitrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 100
Study: 7468946

Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine (Micronephrine) at a dose of 0.9 mg/kg body-weight
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulized salbutamol at a dose of 0.15 mg/kg body-weight
Number of subjects: 10
Study: 6342641

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 640 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/day
Number of subjects: 8
Study: 31083192

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) combined with usual care (UC) for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (UC) alone for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FSN combined with UC
Number of subjects: 60

Group type: COMPARATOR
Intervention: UC alone
Number of subjects: 60
Study: 29998338

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 226

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 226

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 226

Group type: COMPARATOR
Intervention: True acupuncture vs Sham acupuncture
Number of subjects: 226

Group type: COMPARATOR
Intervention: True acupuncture vs Waitlist control
Number of subjects: 226
Study: 27522870

Group type: EXPERIMENTAL
Intervention: Caries Management System (CMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dental care
Number of subjects: 0
Study: 25085357

Group type: EXPERIMENTAL
Intervention: Tacrolimus 180 days and Mycophenolate mofetil 95 days (arm 1)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tacrolimus 150 days and Mycophenolate mofetil 180 days (arm 2)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tacrolimus 150 days, Mycophenolate mofetil 180 days and Sirolimus 80 days (arm 3)
Number of subjects: 208
Study: 23094314

Group type: EXPERIMENTAL
Intervention: Calcipotriene ointment 0.005% applied twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1% applied twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of calcipotriene and tacrolimus (morning calcipotriene and evening tacrolimus)
Number of subjects: 27
Study: 19918980

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 KD) plus ribavirin for 48 weeks in genotype 1/4 patients
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 KD) plus ribavirin for 24 weeks in genotype 2/3 patients
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 KD) plus ribavirin
Number of subjects: 1888
Study: 18007570

Group type: EXPERIMENTAL
Intervention: Guideline concordant treatments for mixed episodes
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Guideline concordant treatments for hypomanic/manic episodes
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Guideline concordant treatments for depressive episodes
Number of subjects: 964
Study: 16326298

Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic internal defibrillation (group B)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Monophasic internal defibrillation (group A)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 134
Study: 12010266

Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg intravenously in the non-operative arm before surgery (systemic presurgery group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg intravenously to the operative arm after tourniquet inflation (regional presurgery group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ketorolac 20 mg intravenously in the non-operative arm after surgery (systemic postsurgery group)
Number of subjects: 47
Study: 9443630

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9086942

Group type: EXPERIMENTAL
Intervention: Community psychiatric nursing (CPN) process
Number of subjects: 8
Study: 2714911

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 74

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 74
Study: 720738

Group type: EXPERIMENTAL
Intervention: Vaporub
Number of subjects: 56

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy children (comparison group)
Number of subjects: 56
Study: 31099864

Group type: EXPERIMENTAL
Intervention: Payments from pharmaceutical companies
Number of subjects: 50
Study: 27888608

Group type: EXPERIMENTAL
Intervention: IVF plus lumbar drainage (LD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IVF alone (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IVF plus LD
Number of subjects: 30
Study: 25856243

Group type: EXPERIMENTAL
Intervention: Standard biofeedback protocol plus daily home use of a Peritron perineometer (intervention)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard biofeedback protocol (control)
Number of subjects: 75